Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
11 December, 2017 11:35 IST
Divis Lab receives import alert for Visakhapatnam facility
Source: IRIS | 21 Mar, 2017, 10.10AM
Comments  |  Post Comment

Divis Laboratories, a pharmaceutical ingredients and intermediates company, has received an Import Alert 66-40 from US Food and Drug Administration (USFDA) for its products manufactured at the company's Unit-II located at Visakhapatnam, Andhra Pradesh on March 20, 2017.

The agency has exempted the following products from the Import Alert-Levetiracetam, Gabapentin, Lamotrigine, Capecitabine, Naproxen sodium, Raltegravir potassium, Atovaquone, Chloropurine, BOC core succinate, 2, 4-wing active ester.

The company along with third party consultants is currently working to address the concerns of the USFDA and is making all efforts to fully meet the compliance requirements. 

Shares of the company declined Rs 138.7, or 17.54%, to trade at Rs 652.00. The total volume of shares traded was 1,228,420 at the BSE (10.02 a.m., Tuesday).



Divis Laboratories Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
Suven Life Sciences secures Product Patents in India and USA - 11-Dec-2017 11:08
Alembic Pharma's associate company gets Fast Track Designation for RP6530 from USFDA - 11-Dec-2017 11:05
IL&FS Engineering bags Pipeline Laying contract worth Rs 2.15 bn - 11-Dec-2017 10:33
Raminfo bags contract from Rajcom Info Services - 11-Dec-2017 10:25
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer